Baudax Bio Inc. (BXRX)

Nasdaq Delist Determination Letter Received; Plan To Be Presented To Regain Compliance


Gregory AurandMedia Inquiries
Senior Healthcare Services & Medical Devices Analyst
May 22, 2023
Report ID: 25875
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Baudax Bio Inc.
Baudax Bio Inc.
Healthcare
Biotechnology
Ticker
BXRX
Current Price
$0.5599 3.69%
Market Cap
$3.4M
Price Target
Refer to Report
Volume
96.1K
52wk Range
$0.5 - $37.72
Related Research Reports
5/22/2023

Nasdaq Delist Determination Letter Received; Plan To Be Presented To Regain Compliance
Nasdaq Delist Determination Letter Received; Plan To Be Presented To Regain Compliance (BXRX)
5/15/2023

1Q 2023 Reported But It’s All About The Pipeline Progress
1Q 2023 Reported But It’s All About The Pipeline Progress (BXRX)
5/2/2023

Offering Closed; Adjusting Estimates for Expected Higher R&D Expenses
Offering Closed; Adjusting Estimates for Expected Higher R&D Expenses (BXRX)
4/26/2023

Full Top Line BX1000 Phase II Results Presented
Full Top Line BX1000 Phase II Results Presented (BXRX)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.